Controversies and opportunities in severe asthma

Current Opinion in Pulmonary Medicine

Volumn 24, Issue 1, 2018, Pages 83-93

  Humbert, Marc ^a,b   Busse, William ^c   Hanania, Nicola A ^d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

anti immunoglobulin E; anti interleukin 5; asthma; biologics; biomarker; endotype; oral corticosteroid; pediatric asthma; phenotype; severe asthma

Indexed keywords

BENRALIZUMAB; CORTICOSTEROID; DUPILUMAB; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 5 ANTIBODY; OMALIZUMAB; ANTI-IGE ANTIBODIES; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; IL5 PROTEIN, HUMAN; INTERLEUKIN 5;

ANTIGEN PRESENTING CELL; ASTHMA; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; EXCRETION FRACTION; HEALTH CARE COST; HUMAN; MAINTENANCE THERAPY; MORBIDITY; PHENOTYPE; PRIMARY PREVENTION; REVIEW; IMMUNOLOGY; PERSONALIZED MEDICINE; PREDICTIVE VALUE;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ASTHMA; BIOLOGICAL PRODUCTS; BIOMARKERS; HUMANS; INTERLEUKIN-5; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS;

EID: 85036605211     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000438     Document Type: Review

References (99)

1. Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 2015; 46:622-639.
2. GINA. Global Strategy for Asthma Management and Prevention 2017. [Available from: Www.Ginasthma.Org]. Accessed 4 August 2017
3. Lang DM. Severe asthma: epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc 2015; 36:418-424.
4. Dean BB, Calimlim BM, Kindermann SL, et al. The impact of uncontrolled asthma on absenteeism and health-related quality of life. J Asthma 2009; 46:861-866.
5. Chiappori A, De Ferrari L, Folli C, et al. Biomarkers and severe asthma: a critical appraisal. Clin Mol Allergy 2015; 13:20.
6. Stoloff SW, Kelly HW. Updates on the use of inhaled corticosteroids in asthma. Curr Opin Allergy Clin Immunol 2011; 11:337-344.
7. O'Byrne PM, Pedersen S, Busse WW, et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006; 129:1478-1485.
8. Busse WW, Pedersen S, Pauwels RA, et al. The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121:1167-1174.
9. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012; 42:650-658.
10. Tabatabaian F, Ledford DK, Casale TB. Biologic and new therapies in asthma. Immunol Allergy Clin North Am 2017; 37:329-343.
11. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47:410-419.
12. Buhl R, Humbert M, Bjermer L, et al., the expert group of the European Consensus Meeting for Severe Eosinophilic Asthma. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J 2017; 49:1700634.
13. Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract 2015; 3:167-174.
14. Parulekar AD, Diamant Z, Hanania NA. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far? Curr Opin Pulm Med 2017; 23:3-11.
15. Kepil Ozdemir S, Bavbek S. Prospects for new and emerging therapeutics in severe asthma: the role of biologics. Expert Rev Respir Med 2017; 11:505-512.
16. Abrams EM, Szefler SJ, Becker AB. Effect of asthma therapies on the natural course of asthma. Ann Allergy Asthma Immunol 2016; 117:627-633.
17. Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804-811.
18. Busse W, Spector S, Rosen K, et al. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol 2013; 132:485-486.e11.
19. Humbert MML, Molimard M. Response to omalizumab treatment according to blood eosinophil count: Results of a French real-world study (STELLAIR). European Respiratory Society Annual Congress 2017; Milan, Italy
20. Normansell R,Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 13:CD003559.
21. Ortega HG, Liu MC, Pavord ID, et al., MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198-1207.
22. Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev 2015; CD010834.
23. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3:355-366.
24. Li J, Wang F, Lin C, et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: a systematic review and meta-Analysis. J Asthma 2017; 54:300-307.
25. Bleecker ER, FitzGerald JM, Chanez P, et al., SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-Acting b2-Agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388:2115-2127.
26. Goldman M, Hirsch I, Zangrilli JG, et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the phase III SIROCCO and CALIMA studies. Curr Med Res Opin 2017; 33:1605-1613.
27. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an antiinterleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet 2016; 388:2128-2141.
28. Nair P, Wenzel S, Rabe KF, et al., ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376:2448-2458.
29. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3:692-701.
30. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 2015; 70:748-756.
31. Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2016; 4:781-796.
32. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-Acting b2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388:31-44.
33. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001; 164:S1-S5.
34. Papathanassiou E, Loukides S, Bakakos P. Severe asthma: anti-IgE or anti-IL-5? Eur Clin Respir J 2016; 3:31813.
35. Draikiwicz S, Oppenheimer J. What is the current role of biologics in the management of patients with severe refractory asthma? Ann Allergy Asthma Immunol 2016; 116:383-387.
36. FajtML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res 2017; 9:3-14.
37. Meteran H, Meteran H, Porsbjerg C, Backer V. Novel monoclonal treatments in severe asthma. J Asthma 2017; 1-21. [Epub ahead of print]
38. Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol 2017; 139:1431-1444.
39. Nachef Z, Krishnan A, Mashtare T, et al. Omalizumab versus mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: a network meta-Analysis. J Asthma 2017; 1-12. [Epub ahead of print]
40. Cockle SM, Stynes G, Gunsoy NB, et al. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison. Respir Med 2017; 123:140-148.
41. Abraham I, Alhossan A, Lee CS, et al. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 2016; 71:593-610.
42. Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-Analysis. Sci Rep 2015; 5:8191.
43. Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol 2015; 26:551-556.
44. Corren J, Kavati A, Ortiz B, et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc 2017; 38:250-263.
45. Alhossan A, Lee CS, MacDonald K, et al. Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-Analysis. J Allergy Clin Immunol Pract 2017; 5:1362-1370.e2.
46. Grimaldi-Bensouda L, Zureik M, Aubier M, et al., Pharmacoepidemiology of Asthma and Xolair (PAX) StudyGroup. Does omalizumabmake a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma. Chest 2013; 143: 398-405.
47. Menzella F, Galeone C, Formisano D, et al. Real-life efficacy of omalizumab after 9 years of follow-up. Allergy Asthma Immunol Res 2017; 9:368-372.
48. Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 2013; 144:411-419.
49. Pillai P, Chan YC, Wu SY, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in nonatopic asthma. Eur Respir J 2016; 48:1593-1601.
50. Gaga M, Zervas E, Humbert M. Targeting immunoglobulin E in nonatopic asthma: crossing the red line? Eur Respir J 2016; 48:1538-1540.
51. Sattler C, Garcia G, Humbert M. Novel targets of omalizumab in asthma. Curr Opin Pulm Med 2017; 23:56-61.
52. Varricchi G, Canonica GW. The role of interleukin 5 in asthma. Expert Rev Clin Immunol 2016; 12:903-905.
53. Kim AS, Doherty TA. New and emerging therapies for asthma. Ann Allergy Asthma Immunol 2016; 116:14-17.
54. Cabon Y, Molinari N, Marin G, et al. Comparison of antiinterleukin-5 therapies in patients with severe asthma: global and indirect meta-Analyses of randomized placebo-controlled trials. Clin Exp Allergy 2017; 47:129-138.
55. Casale TB. Biologics and biomarkers for asthma, urticaria, and nasal polyposis. J Allergy Clin Immunol 2017; 139:1411-1421.
56. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189-1197.
57. Bagnasco D, Ferrando M, Varricchi G, et al. A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol 2016; 170:122-131.
58. Pavord ID, Hilvering B, Shrimanker R. Emerging biologics in severe asthma. Immunol Allergy Clin North Am 2016; 36:609-623.
59. Sulaiman I, Lim JC, Soo HL, et al. Molecularly targeted therapies for asthma: current development, challenges and potential clinical translation. Pulm Pharmacol Ther 2016; 40:52-68.
60. AstraZeneca provides update on STRATOS 1 Phase III trial of tralokinumab in severe, uncontrolled asthma [press release]. 10 May 2017. [Accessed 4 August 2017]
61. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for understanding mechanisms of severe asthma. Eur Respir J 2003; 22:470-477.
62. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebocontrolled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188:1294-1302.
63. Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet 2015; 386:1086-1096.
64. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
65. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651-659.
66. European Medicines Agency. Xolair: EPAR-product information. 9 September 2016. [Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000606/WC500057298.pdf]
67. NICE. Mepolizumab for treating severe refractory eosinophilic asthma 2017 [Available from: https://www.nice.org.uk/guidance/ta431]. [Accessed 4 August 2017]
68. Skloot GS. Asthma phenotypes and endotypes: a personalized approach to treatment. Curr Opin Pulm Med 2016; 22:3-9.
69. Froidure A, Mouthuy J, Durham SR, et al. Asthma phenotypes and IgE responses. Eur Respir J 2016; 47:304-319.
70. Ciprandi G, Tosca MA, Silvestri M, et al. Inflammatory biomarkers for asthma endotyping and consequent personalized therapy. Expert Rev Clin Immunol 2017; 13:715-721.
71. Agache I, Akdis CA. Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine. Allergol Int 2016; 65:243-252.
72. Opina MT, Moore WC. Phenotype-driven therapeutics in severe asthma. Curr Allergy Asthma Rep 2017; 17:10.
73. Iordanidou M, Loukides S, Paraskakis E. Asthma phenotypes in children and stratified pharmacological treatment regimens. Expert Rev Clin Pharmacol 2017; 10:293-303.
74. Deliu M, Belgrave D, Sperrin M, et al. Asthma phenotypes in childhood. Expert Rev Clin Immunol 2017; 13:705-713.
75. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343-373.
76. Luskin AT, Antonova EN, Broder MS, et al. Healthcare resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis. Clinicoecon Outcomes Res 2016; 8:641-648.
77. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013; 9:30.
78. Aljebab F, Choonara I, Conroy S. Long-course oral corticosteroid toxicity in children. Arch Dis Child 2016; 101:e2.
79. Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the 'realworld' effectiveness of omalizumab in allergic asthma. Respir Med 2013; 107:1141-1151.
80. Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol 2017. [Epub ahead of print]
81. Zeiger RS, Schatz M, Li Q, et al. Burden of chronic oral corticosteroid use by adults with persistent asthma. J Allergy Clin Immunol Pract 2017; 5: 1050-1060.e9.
82. Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-Associated adverse events: a systematic literature review. Clin Ther 2011; 33:1413-1432.
83. Siergiejko Z, Swiebocka E, Smith N, et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin 2011; 27:2223-2228.
84. Barnes N, Menzies-Gow A, Mansur AH, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma 2013; 50:529-536.
85. Hedlin G. Management of severe asthma in childhood: state of the art and novel perspectives. Pediatr Allergy Immunol 2014; 25:111-121.
86. Bush A, Pedersen S, Hedlin G, et al., PSACI (Problematic Severe Asthma in Childhood Initiative) group. Pharmacological treatment of severe, therapyresistant asthma in children: what can we learn from where? Eur Respir J 2011; 38:947-958.
87. Xia Y, Kelton CM, Xue L, et al. Safety of long-Acting beta agonists and inhaled corticosteroids in children and adolescents with asthma. Ther Adv Drug Saf 2013; 4:254-263.
88. Hossny E, Rosario N, Lee BW, et al. The use of inhaled corticosteroids in pediatric asthma: update. World Allergy Organ J 2016; 9:26.
89. Stempel DA, Szefler SJ, Pascoe SJ. Salmeterol and fluticasone propionate in children with asthma. N Engl J Med 2016; 375:e46.
90. Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367:904-912.
91. Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-Analysis. PLoS One 2015; 10:e0133428.
92. De Leonibus C, Attanasi M, Roze Z, et al. Influence of inhaled corticosteroids on pubertal growth and final height in asthmatic children. Pediatr Allergy Immunol 2016; 27:499-506.
93. Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J 2015; 46:856-859.
94. Baena-Cagnani CE, Teijeiro A, Canonica GW. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Curr Opin Allergy Clin Immunol 2015; 15:267-271.
95. Mauri P, Riccio AM, Rossi R, et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumabtreated severe asthma patients. Immunol Lett 2014; 162:2-10.
96. Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 2012; 83: 520-528.
97. Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol 2012; 25:475-484.
98. Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136:1476-1485.
99. Esquivel A, Busse WW, Calatroni A, et al. Effects of omalizumab on rhinovirus infections, illnesses and exacerbations of asthma. Am J Respir Crit Care Med 2017. [Epub ahead of print]